Belite Reports Positive Late-Stage Trial Results for Tinlarebant in Treating Stargardt Disease

Belite has announced positive results from a late-stage clinical trial for its experimental drug, tinlarebant, aimed at treating Stargardt disease, a rare genetic eye condition. The findings position the company to potentially secure regulatory approval for what could become the first approved treatment for this condition. Stargardt disease, which leads to progressive vision loss and currently lacks any FDA-approved therapies, affects approximately one in 8,000 to 10,000 individuals worldwide.

The trial, known as the DRAGON study, evaluated the safety and efficacy of tinlarebant in patients with Stargardt disease. Results reportedly met key endpoints, demonstrating significant progress in addressing the unmet medical need associated with this degenerative retinal disorder. Belite has been recognized as a strong performer in the biopharmaceutical sector since 2022 and now appears poised to advance its drug candidate toward regulatory submission. If approved, tinlarebant would represent a milestone in ophthalmology by providing a treatment option for those living with Stargardt disease.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

Related posts:

PET Plastic Recycling: A Key Component in Promoting Circular Economies Biotech IPOs Reach 25 in 2024 Amid Rising Nasdaq Biotech Index Additions Omada Develops Threat Model to Assess AI Risks in Healthcare Data Security and Compliance Study Estimates Nearly 20 Percent of UTIs in Southern California Linked to E. coli from Contaminated Meat

Author

GOAI